A Phase 2 interventional study of Sevelamer carbonate and Sevelamer carbonate in HIV-1 Infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-11.
Sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
HIV-infected people can have an increase in inflammation in their body organs, even after taking anti-HIV medicines.
Sevelamer carbonate is used to bind phosphate in dialysis patients. It can also bind endotoxin in the gut and lowers endotoxin levels in the blood of dialysis patients. Sevelamer carbonate decreases the inflammation endotoxin causes in dialysis patients.
A5296 is a phase II, single-arm study to evaluate the effect of 8 weeks of sevelamer carbonate administration on markers of microbial translocation and T-cell activation in the blood in chronically HIV-infected subjects not receiving ART.
HIV-infected people can have an increase in inflammation in their body organs, even after taking anti-HIV medicines. Inflammation is a normal body reaction to any infection. However, if inflammation lasts a long time like in HIV infection, it may lead to complications, such as heart disease, cancer, liver disease, and problems with thinking. Also, HIV-infected people with high inflammation have lower CD4+ T-cell counts (cells that fight infection). Many HIV researchers are studying the harmful effects of this prolonged inflammation and possible ways to prevent these complications.
The increase in inflammation in HIV-infected people may be caused by HIV or by other factors such as parts of bacteria. These bacterial pieces, called endotoxins, do not cause harm in the intestine (gut). However, in HIV infection, there is damage to the gut that allows endotoxins to cross from the gut into the blood. These endotoxins then cause inflammation in the body. New research is focusing on strategies to reduce the levels of endotoxin as a way to decrease inflammation.
A drug called sevelamer carbonate is used to bind phosphate in dialysis patients. However, sevelamer carbonate also binds endotoxin in the gut and lowers endotoxin levels in the blood of dialysis patients. Sevelamer carbonate also decreases the inflammation endotoxin causes in dialysis patients. This study will see if sevelamer carbonate can have the same effects in HIV-infected patients.
A5296 is a phase II, single-arm study to evaluate the effect of 8 weeks of sevelamer carbonate administration on markers of microbial translocation as well as monocyte and T-cell activation in the blood in chronically HIV-infected subjects with CD4+ T-cell count ≥ 400 cells/mm3 not receiving ART. This study enrolled 40 subjects. To assess whether there is a persistent effect of study drug, subjects were observed for an additional 8 weeks off sevelamer carbonate and changes in biomarkers were monitored.
As A5296 is a phase II study of biologic activity, the primary and secondary analyses are as-treated, limited to subjects who have data for baseline and week 8 and who remain on study treatment through week 8. For any subject who initiated antiretroviral treatment (ART), analyses only included data collected prior to the time ART was started.
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections is the lead sponsor of 70 studies on the registry; 3 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects participating in sexual activity that could lead to pregnancy must agree to use at least one of the following forms of for at least 30 days prior to study entry until the final study visit:
Exclusion Criteria:
NOTE A: Use of inhaled steroids, nasal steroids, topical steroids, or the equivalent of 10 mg of prednisone or less per day or a less than 2-week course of oral steroids is not exclusionary.
NOTE B: A single course of 1% hydrocortisone cream applied up to 3 times a day to \<10 square inches area for \<2 weeks is permitted while on study. Use of all other topical steroids is excluded.
NOTE: Potential subjects with chronic or C virus infection who do not have known cirrhosis or severe liver disease may participate in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
Drug: Sevelamer carbonate · Device: Sevelamer carbonate
Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
Also known as: Renvela
Also known as: Renvela
Change in Endotoxin
Change in LPS from baseline to week 8, where baseline value is the average of pre-entry and entry values.
Time frame: baseline and Week 8
Change in Soluble CD14 (sCD14)
Change in soluble CD14 (sCD14) from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Endotoxin
Change in endotoxin from baseline to week 4, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in Endotoxin
Change in endotoxin from week 8 to week 16
Time frame: week 8 and week 16
Change in sCD14
Change in sCD14 from baseline to week 4, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in sCD14
Change in sCD14 from week 8 to week 16
Time frame: week 8 and week 16
Change in CD4+ T-cell Activation
Change from baseline to week 8 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in CD4+ T-cell Activation
Change from baseline to week 4 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in CD4+ T-cell Activation
Change from week 8 to week 16 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+
Time frame: week 8 and week 16
Change in CD8+ T-cell Activation
Change from baseline to week 4 in CD8+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in CD8+ T-cell Activation
Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from baseline to week 8, where baseline is the average of pre-entry and entry
Time frame: Baseline and Week 8
Change in CD8+ T-cell Activation
Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from week 8 to week 16
Time frame: week 8 and week 16
Change in Proportion of Cycling CD8+
Change from baseline to week 4 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in Proportion of Cycling CD8+
Change from baseline to week 8 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Proportion of Cycling CD8+
Change from week 8 to week 16 in cycling CD8+ , defined as the %Ki67+
Time frame: from week 8 to week 16
Change in Proportion of Cycling CD4+
Change from baseline to week 4 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in Proportion of Cycling CD4+
Change from baseline to week 8 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Proportion of Cycling CD4+
Change from week 8 to week 16 in cycling CD4+ , defined as the %Ki67+
Time frame: week 8 and week 16
Change in Blood Phosphate Levels
Change in blood phosphate levels from baseline to week 4, where baseline value is the average of pre-entry and entry
Time frame: from baseline to week 4
Change in Blood Phosphate Levels
Change in blood phosphate levels from baseline to week 8
Time frame: Baseline to Week 8
Change in Blood Phosphate Levels
Change in blood phosphate levels from week 8 to week 16
Time frame: from week 8 to week 16
Change in log10 HIV RNA Levels
Change in log10 HIV RNA levels from baseline to week 4, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in log10 HIV RNA Levels
Change in log10 HIV RNA levels from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in log10 HIV RNA Levels
Change in log10 HIV RNA levels from week 8 to week 16
Time frame: week 8 and week 16
Change in CD4+ T-cell Counts
Change in CD4+ T-cell counts from baseline to week 4, where baseline is the average of pre-entry and entry
Time frame: baseline and week 4
Change in CD4+ T-cell Counts
Change in CD4+ T-cell counts from baseline to week 8, where baseline is the average of pre-entry and entry
Time frame: baseline and week 8
Change in CD4+ T-cell Counts
Change in CD4+ T-cell counts from week 8 to week 16
Time frame: week 8 and week 16
Change in IL-6
Changes in levels of systemic inflammation marker IL-6 from baseline to week 4, where baseline is the average of pre-entry and entry
Time frame: baseline and week 4
Change in IL-6
Changes in levels of systemic inflammation marker IL-6 from baseline to week 8, where baseline is the average of pre-entry and entry
Time frame: baseline and week 8
Change in IL-6
Changes in levels of systemic inflammation marker IL-6 from week 8 to week 16
Time frame: week 8 and week 16
Change in C-reactive Protein (CRP)
Changes in levels of systemic inflammation marker CRP from baseline to week 4, where baseline is the average of pre-entry and entry
Time frame: baseline and week 4
Change in CRP
Changes in levels of systemic inflammation marker CRP from baseline to week 8, where baseline is the average of pre-entry and entry
Time frame: Baseline and Week 8
Change in CRP
Changes in levels of systemic inflammation marker CRP from week 8 to week 16, where baseline is the average of pre-entry and entry
Time frame: week 8 and week 16
Change in D-dimer
Change in levels of coagulation biomarker d-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in D-dimer
Change in levels of coagulation biomarker d-dimer from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in D-dimer
Change in levels of coagulation biomarker d-dimer from week 8 to week 16
Time frame: week 8 and week 16
Change in Tissue Factor
Change in levels of coagulation biomarker tissue factor from baseline to week 4, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 4
Change in Tissue Factor
Change in levels of coagulation biomarker tissue factor from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Tissue Factor
Change in levels of coagulation biomarker tissue factor from week 8 to week 16
Time frame: week 8 and week 16
Change in Total Cholesterol
Change in total cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Total Cholesterol
Change in total cholesterol from week 8 to week 16
Time frame: week 8 and week 16
Change in LDL Cholesterol
Change in fasting LDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in LDL Cholesterol
Change in fasting LDL cholesterol from week 8 to week 16
Time frame: week 8 and week 16
Change in HDL Cholesterol
Change in fasting HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in HDL Cholesterol
Change in fasting HDL cholesterol from week 8 to week 16
Time frame: from week 8 to week 16
Change in Non-HDL Cholesterol
Change in non-HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Non-HDL Cholesterol
Change in non-HDL cholesterol from week 8 to week 16
Time frame: week 8 and week 16
Change in Fasting Glucose
Change in fasting glucose from baseline to week 8, where baseline value is the average of pre-entry and entry
Time frame: baseline and week 8
Change in Fasting Glucose
Change in fasting glucose from week 8 to week 16
Time frame: week 8 and week 16
Primary Adverse Events
Number of subjects experiencing primary adverse events, defined as all reported Grade ≥ 2 signs and symptoms, Grade ≥ 2 laboratory abnormalities and other serious adverse events (SAEs)
Time frame: baseline and week 16
A5296 accrual opened under protocol version 1.0 on 11/21/11, and the first subject was enrolled on 12/29/11. Accrual to the study closed on 8/1/12, with a total of 40 subjects enrolled from 15 sites within the US.
| Milestone | Sevelamer Carbonate |
|---|---|
| Started | 40 |
| Completed | 36 |
| Not completed | 4 |
| Withdrew: Loss to follow-up | 3 |
| Withdrew: Art initiation | 1 |
Change in LPS from baseline to week 8, where baseline value is the average of pre-entry and entry values.
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in Endotoxin | 0.20 (-4.06 to 5.81) |
Change in soluble CD14 (sCD14) from baseline to week 8, where baseline value is the average of pre-entry and entry
| ug/mL | Sevelamer Carbonate |
|---|---|
| Change in Soluble CD14 (sCD14) | -0.02 (-0.18 to 0.06) |
Change in endotoxin from baseline to week 4, where baseline value is the average of pre-entry and entry
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in Endotoxin | 1.08 (-2.51 to 7.71) |
Change in endotoxin from week 8 to week 16
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in Endotoxin | -2.39 (-8.04 to 2.65) |
Change in sCD14 from baseline to week 4, where baseline value is the average of pre-entry and entry
| ug/mL | Sevelamer Carbonate |
|---|---|
| Change in sCD14 | -0.09 (-0.23 to 0.11) |
Change in sCD14 from week 8 to week 16
| ug/mL | Sevelamer Carbonate |
|---|---|
| Change in sCD14 | 0.06 (-0.03 to 0.24) |
Change from baseline to week 8 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in CD4+ T-cell Activation | 0.050 (-0.650 to 2.600) |
Change from baseline to week 4 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in CD4+ T-cell Activation | 0.4 (-0.95 to 1.2) |
Change from week 8 to week 16 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+
| percentage | Sevelamer Carbonate |
|---|---|
| Change in CD4+ T-cell Activation | 0.45 (-0.80 to 1.60) |
Change from baseline to week 4 in CD8+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in CD8+ T-cell Activation | -0.05 (-4.35 to 3.15) |
Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from baseline to week 8, where baseline is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in CD8+ T-cell Activation | -0.450 (-1.75 to 1.95) |
Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from week 8 to week 16
| percentage | Sevelamer Carbonate |
|---|---|
| Change in CD8+ T-cell Activation | -0.15 (-1.9 to 6) |
Change from baseline to week 4 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in Proportion of Cycling CD8+ | -0.125 (-0.55 to 0.275) |
Change from baseline to week 8 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in Proportion of Cycling CD8+ | 0.1 (-0.425 to 0.775) |
Change from week 8 to week 16 in cycling CD8+ , defined as the %Ki67+
| percentage | Sevelamer Carbonate |
|---|---|
| Change in Proportion of Cycling CD8+ | 0.300 (-0.5 to 0.9) |
Change from baseline to week 4 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in Proportion of Cycling CD4+ | 0.125 (-0.375 to 0.575) |
Change from baseline to week 8 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry
| percentage | Sevelamer Carbonate |
|---|---|
| Change in Proportion of Cycling CD4+ | 0.025 (-0.575 to 0.40) |
Change from week 8 to week 16 in cycling CD4+ , defined as the %Ki67+
| percentage | Sevelamer Carbonate |
|---|---|
| Change in Proportion of Cycling CD4+ | 0.2 (-0.3 to 0.8) |
Change in blood phosphate levels from baseline to week 4, where baseline value is the average of pre-entry and entry
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Blood Phosphate Levels | 0 (-0.20 to 0.60) |
Change in blood phosphate levels from baseline to week 8
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Blood Phosphate Levels | -0.1 (-0.3 to 0.2) |
Change in blood phosphate levels from week 8 to week 16
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Blood Phosphate Levels | 0.10 (-0.30 to 0.40) |
Change in log10 HIV RNA levels from baseline to week 4, where baseline value is the average of pre-entry and entry
| log10(copies/mL) | Sevelamer Carbonate |
|---|---|
| Change in log10 HIV RNA Levels | 0.02 (-0.09 to 0.14) |
Change in log10 HIV RNA levels from baseline to week 8, where baseline value is the average of pre-entry and entry
| log10(copies/mL) | Sevelamer Carbonate |
|---|---|
| Change in log10 HIV RNA Levels | -0.02 (-0.12 to 0.10) |
Change in log10 HIV RNA levels from week 8 to week 16
| log10(copies/mL) | Sevelamer Carbonate |
|---|---|
| Change in log10 HIV RNA Levels | 0.16 (-0.11 to 0.31) |
Change in CD4+ T-cell counts from baseline to week 4, where baseline is the average of pre-entry and entry
| cells/mm^3 | Sevelamer Carbonate |
|---|---|
| Change in CD4+ T-cell Counts | -25 (-86 to 40) |
Change in CD4+ T-cell counts from baseline to week 8, where baseline is the average of pre-entry and entry
| cells/mm^3 | Sevelamer Carbonate |
|---|---|
| Change in CD4+ T-cell Counts | -14 (-70 to 45) |
Change in CD4+ T-cell counts from week 8 to week 16
| cells/mm^3 | Sevelamer Carbonate |
|---|---|
| Change in CD4+ T-cell Counts | -1 (-93 to 69) |
Changes in levels of systemic inflammation marker IL-6 from baseline to week 4, where baseline is the average of pre-entry and entry
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in IL-6 | 0.28 (-0.13 to 0.72) |
Changes in levels of systemic inflammation marker IL-6 from baseline to week 8, where baseline is the average of pre-entry and entry
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in IL-6 | -0.02 (-0.58 to 0.63) |
Changes in levels of systemic inflammation marker IL-6 from week 8 to week 16
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in IL-6 | 0.19 (-0.43 to 1.07) |
Changes in levels of systemic inflammation marker CRP from baseline to week 4, where baseline is the average of pre-entry and entry
| ng/mL | Sevelamer Carbonate |
|---|---|
| Change in C-reactive Protein (CRP) | -141 (-1283.5 to 845) |
Changes in levels of systemic inflammation marker CRP from baseline to week 8, where baseline is the average of pre-entry and entry
| ng/mL | Sevelamer Carbonate |
|---|---|
| Change in CRP | 45.5 (-652.5 to 1539.5) |
Changes in levels of systemic inflammation marker CRP from week 8 to week 16, where baseline is the average of pre-entry and entry
| ng/mL | Sevelamer Carbonate |
|---|---|
| Change in CRP | -34 (-493 to 527) |
Change in levels of coagulation biomarker d-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry
| ng/mL | Sevelamer Carbonate |
|---|---|
| Change in D-dimer | 5.95 (-28.87 to 55.02) |
Change in levels of coagulation biomarker d-dimer from baseline to week 8, where baseline value is the average of pre-entry and entry
| ng/mL | Sevelamer Carbonate |
|---|---|
| Change in D-dimer | 20.30 (-16.08 to 74.90) |
Change in levels of coagulation biomarker d-dimer from week 8 to week 16
| ng/mL | Sevelamer Carbonate |
|---|---|
| Change in D-dimer | -17.15 (-66.00 to 25.80) |
Change in levels of coagulation biomarker tissue factor from baseline to week 4, where baseline value is the average of pre-entry and entry
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in Tissue Factor | -2.47 (-6.03 to 0.15) |
Change in levels of coagulation biomarker tissue factor from baseline to week 8, where baseline value is the average of pre-entry and entry
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in Tissue Factor | -2 (-6.7 to -0.1) |
Change in levels of coagulation biomarker tissue factor from week 8 to week 16
| pg/mL | Sevelamer Carbonate |
|---|---|
| Change in Tissue Factor | 3.8 (0 to 8) |
Change in total cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Total Cholesterol | -12.5 (-28.50 to 5.50) |
Change in total cholesterol from week 8 to week 16
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Total Cholesterol | 9 (-4 to 25) |
Change in fasting LDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in LDL Cholesterol | -18.25 (-32.20 to 1.50) |
Change in fasting LDL cholesterol from week 8 to week 16
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in LDL Cholesterol | 14.20 (-0.50 to 32.5) |
Change in fasting HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in HDL Cholesterol | 0.50 (-5 to 4) |
Change in fasting HDL cholesterol from week 8 to week 16
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in HDL Cholesterol | 1 (-3 to 5) |
Change in non-HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Non-HDL Cholesterol | -12 (-25 to 2) |
Change in non-HDL cholesterol from week 8 to week 16
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Non-HDL Cholesterol | 4 (-2 to 24) |
Change in fasting glucose from baseline to week 8, where baseline value is the average of pre-entry and entry
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Fasting Glucose | -2 (-12.75 to 2.92) |
Change in fasting glucose from week 8 to week 16
| mg/dL | Sevelamer Carbonate |
|---|---|
| Change in Fasting Glucose | 3.5 (-3 to 15) |
Number of subjects experiencing primary adverse events, defined as all reported Grade ≥ 2 signs and symptoms, Grade ≥ 2 laboratory abnormalities and other serious adverse events (SAEs)
| participants | Sevelamer Carbonate |
|---|---|
| Primary Adverse Events | 28 |
Collected over AEs reported from study enrollment until study completion at week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sevelamer Carbonate | — | 2/40 (5%) | 32/40 (80%) |
| Event | Sevelamer Carbonate |
|---|---|
| CellulitisInfections and infestations | 1/40 |
| Joint injuryInjury, poisoning and procedural complications | 1/40 |
| Event | Sevelamer Carbonate |
|---|---|
| Blood cholesterol increasedInvestigations | 11/40 |
| Blood phosphorus decreasedInvestigations | 10/40 |
| Blood bicarbonate decreasedInvestigations | 9/40 |
| Blood glucose increasedInvestigations | 9/40 |
| Blood calcium decreasedInvestigations | 8/40 |
| Low density lipoprotein increasedInvestigations | 6/40 |
| Blood glucose decreasedInvestigations | 5/40 |
| Blood sodium decreasedInvestigations | 3/40 |
| ConjunctivitisEye disorders | 2/40 |
| Abdominal painGastrointestinal disorders | 2/40 |
| Age, Categorical(Participants) | Sevelamer Carbonate |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 39 |
| >=65 years | 1 |
| Age, Continuous(years) | Sevelamer Carbonate |
|---|---|
| Median | 44 (34 to 51) |
| Sex: Female, Male(Participants) | Sevelamer Carbonate |
|---|---|
| Female | 11 |
| Male | 29 |
| Race/Ethnicity, Customized(participants) | Sevelamer Carbonate |
|---|---|
| White non-Hispanic | 10 |
| Black Non-Hispanic | 24 |
| Hispanic (regardless of Race) | 6 |
| Region of Enrollment(participants) | Sevelamer Carbonate |
|---|---|
| United States | 40 |
| Log10 HIV-1 RNA(copies/mL) | Sevelamer Carbonate |
|---|---|
| Median | 3.58 (2.94 to 4.17) |
| CD4 count(cells/mm^3) | Sevelamer Carbonate |
|---|---|
| Median | 580 (494 to 716) |
The record gives a start of Nov 2011, a primary completion of Sep 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevelamer
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections